Actin Cytoskeleton in Cancer Progression and Metastasis - Part A. Este artículo no está disponible.
Idioma: inglés
Editorial: Academic Press, 2020
- Tapa dura
- Nuevo

Librería: Revaluation Books, Exeter, Reino UnidoRevaluation Books
Vendedor de IberLibro desde 6 de enero de 2003
Condición: Nuevo
EUR 238,44
Descripción del artículo del vendedor
277 pages. 9.50x6.50x0.75 inches. In Stock. This item is printed on demand.
N° de ref. del artículo __0128212810
- Título
- Actin Cytoskeleton in Cancer Progression and Metastasis - Part A
- Autor
- Galluzzi, Lorenzo/ Thomas, Clement
- Editorial
- Academic Press
- Año de publicación
- 2020
- Estado
- Brand New
- Encuadernación
- Hardcover
- Idioma
- inglés
- ISBN 10
- 0128212810
- ISBN 13
- 9780128212813
- Peso del artículo
- 5,31 kilogramos
Actin Cytoskeleton in Cancer Progression and Metastasis - Part A, Volume 355 in the International Review of Cell and Molecular Biology series, provides an overview of the roles of the actin cytoskeleton and some of its key structural regulators, including WASp, Paxillin, Myosin, Testin, L-Plastin and profilin, in central processes underlying cancer progression and metastasis, such as changes in cell morphology and gene expression, acquisition of migratory and invasive capabilities, and evasion from the immune response.
- Provides comprehensive and timely reviews on actin cytoskeleton and its regulators in cancer biology
- Offers a wide range of perspectives for basic and translational research
- Discusses opportunities and challenges for translating knowledge of tumor cell actin cytoskeleton into clinical applications
“Sinopsis” puede pertenecer a otra edición de este título.
Acerca del autor
Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals:
OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.
Fernando Aranda holds a BSc in Biology (2006) and Biochemistry (2007) from the University of Navarra. Then, he specialized in different strategies of Cancer Immunotherapy with a MSc in Biomedical Research (2008), and a PhD Degree (2012) from the University of Navarra (Pamplona) – Cima University of Navarra. More than 12 years in translational research focus on antitumor immune responses and Cancer Immunotherapy. Author of 64 publications indexed in PubMed in prestigious international journals, with h-index 30 and 4,296 cites (October 2022). He completed the Program of Sara Borrell (ISCIII) -competitive Postdoctoral contract- in the Group of Immune Receptors of the Innate and Adaptive System (IDIBAPS), Barcelona (2016-2018). Co-author of 1 invention patent: Composition based on the fibronectin domain A for the treatment of melanoma - WO/2011/101332. In 2012, Fernando Aranda obtained a Scientific Award, "Profesor Durantez" II Edición, for the best scientific article in Tumor Immunology by Fundación LAIR. Recently, Fernando Aranda awarded a competitive Research Fellow contract “Miguel Servet tipo I by Instituto de Salud Carlos III, to continue his independent researcher career (IP) in cancer immunotherapy issues. Specifically, he is involved in Translational Immunotherapy of Peritoneal Carcinomatosis. Currently, Fernando Aranda leads a research group in cooperation with Dr. Pedro Berraondo.
“Acerca de” puede pertenecer a otra edición de este título.